Harvard Bioscience (HBIO) vs Stereotaxis (STXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Harvard Bioscience (HBIO) has outperformed Stereotaxis (STXS) over the past year, gaining 84.8% versus a loss of 68.9%. Over five years, STXS leads with a -81.3% price change compared with -88.1% for HBIO. Stereotaxis is the larger company by market cap ($110.8 million vs $37.7 million), about 2.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HBIO | STXS |
|---|---|---|
| Share price | $8.29 | $1.11 |
| Market cap | $37.72M | $110.75M |
| 1-day change | +1.91% | -0.42% |
| YTD return | +21.34% | -51.74% |
| 1-year return | +84.77% | -68.91% |
| 5-year return | -88.11% | -81.28% |
| Forward P/E | 12.84 | — |
| EPS (TTM) | $-2.31 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.40 | $3.42 |
| 52-week low | $3.80 | $1.09 |
| Distance from 52-week high | -11.86% | -67.68% |
| Analyst consensus | none | none |
| Avg. price target upside | -9.47% | +171.42% |
| Average volume | 17.98K | 808.41K |
| Shares outstanding | 4.55M | 100.20M |
| Employees | 316 | 131 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Stereotaxis is about 2.9 times larger than Harvard Bioscience by market value ($110.75M vs $37.72M).
- HBIO has outperformed STXS by 153.7 percentage points over the past year.
- The two companies sit in different sectors: Harvard Bioscience in Industrials and Stereotaxis in Health Care.
About Harvard Bioscience
HBIO stock →Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 316 employees
About Stereotaxis
STXS stock →Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 131 employees
HBIO vs STXS FAQ
Which is bigger, Harvard Bioscience or Stereotaxis?
Stereotaxis (STXS) is larger, with a market capitalization of $110.75M compared with $37.72M for Harvard Bioscience (HBIO).
Which stock has performed better over the past year, HBIO or STXS?
HBIO returned +84.77% over the past 12 months, compared with -68.91% for STXS (price return, excluding dividends). Past performance does not predict future results.
Are Harvard Bioscience and Stereotaxis in the same industry?
No. Harvard Bioscience is in the Industrials sector, while Stereotaxis is in Health Care.